Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccinia-CEA-TRICOM and Fowlpox-CEA-TRICOM in High-Risk Breast Cancer
NCT00052351Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2002
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant vaccinia-CEA(6D)-TRICOM vaccine and recombinant fowlpox-CEA(6D)/TRICOM in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Immunological effects of vaccine schedules. Started Sep 2002; status: completed.
02
Drugs
recombinant vaccinia-CEA(6D)-TRICOM vaccinerecombinant fowlpox-CEA(6D)/TRICOM
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00052351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052351.